Medulloblastoma — Trials

Medulloblastoma — Trials · CancerIndex

Clinical trials

Registered studies

204 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 61
Recruiting: 29
Ph III recruiting: 2
Growth YoY: —
Industry share: 5%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (28)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06485908	Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma(MEPENDAX)	not yet recruiting	Phase 1 / Phase 2	40	Assistance Publique Hopitaux De MarseilleOTHER	0	Jul 3, 2024	clinicaltrials

Data updated 22 days agoSource updated Jul 3, 2024source: clinicaltrials